Trade Viking Therapeutics, Inc. - VKTX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.15 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023512% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.00129% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 31.56 |
| Open | 31.64 |
| 1-Year Change | -11.35% |
| Day's Range | 31.61 - 35.7 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Feb 21, 2025 | 34.02 | 2.13 | 6.68% | 31.89 | 36.28 | 31.42 |
| Feb 20, 2025 | 31.56 | -0.48 | -1.50% | 32.04 | 33.17 | 31.08 |
| Feb 19, 2025 | 32.27 | 3.22 | 11.08% | 29.05 | 34.29 | 28.90 |
| Feb 18, 2025 | 29.21 | -1.14 | -3.76% | 30.35 | 30.62 | 29.19 |
| Feb 14, 2025 | 30.43 | 0.92 | 3.12% | 29.51 | 30.79 | 29.40 |
| Feb 13, 2025 | 29.43 | -0.30 | -1.01% | 29.73 | 30.05 | 28.59 |
| Feb 12, 2025 | 29.27 | -0.18 | -0.61% | 29.45 | 30.21 | 29.05 |
| Feb 11, 2025 | 29.91 | 0.57 | 1.94% | 29.34 | 29.91 | 29.03 |
| Feb 10, 2025 | 30.11 | -2.50 | -7.67% | 32.61 | 32.61 | 29.84 |
| Feb 7, 2025 | 32.49 | 1.18 | 3.77% | 31.31 | 32.82 | 30.78 |
| Feb 6, 2025 | 31.39 | 0.69 | 2.25% | 30.70 | 33.28 | 29.86 |
| Feb 5, 2025 | 33.43 | 0.85 | 2.61% | 32.58 | 33.83 | 32.31 |
| Feb 4, 2025 | 32.30 | 1.10 | 3.53% | 31.20 | 33.92 | 30.84 |
| Feb 3, 2025 | 31.46 | 0.21 | 0.67% | 31.25 | 32.31 | 31.06 |
| Jan 31, 2025 | 32.66 | -1.38 | -4.05% | 34.04 | 34.67 | 32.25 |
| Jan 30, 2025 | 33.65 | -0.30 | -0.88% | 33.95 | 34.17 | 33.27 |
| Jan 29, 2025 | 33.34 | -0.61 | -1.80% | 33.95 | 34.50 | 33.12 |
| Jan 28, 2025 | 34.25 | 0.20 | 0.59% | 34.05 | 34.67 | 32.70 |
| Jan 27, 2025 | 33.39 | -0.24 | -0.71% | 33.63 | 34.60 | 32.85 |
| Jan 24, 2025 | 34.45 | -0.05 | -0.14% | 34.50 | 35.88 | 34.12 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
Viking Therapeutics, Inc. Company profile
About Viking Therapeutics Inc
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for metabolic and endocrine disorders. The Company's lead clinical program's drug candidate, VK2809, is an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß). The Company is conducting VOYAGE study, a phase II b clinical trial of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH). It is also developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRß for X-linked adrenoleukodystrophy (X-ALD), a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. It is engaged in a phase I b clinical trial of VK0214 in patients with X-ALD. Its other clinical programs include VK5211, an orally available, non-steroidal selective androgen receptor modulator (SARM).
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Viking Therapeutics Inc revenues was not reported. Net loss increased 39% to $55M. Higher net loss reflects Other Research and Development. increase of 42% to $43.4M (expense), Interest Income - Net decrease of 78% to $703K (income), Stock-based Compensation in R&D increase of 19% to $1.6M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.54 to -$0.71.
| Industry: | Bio Therapeutic Drugs |
9920 Pacific Heights Blvd, Suite 350
SAN DIEGO
CALIFORNIA 92121
US
News
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025
Ripple XRP price prediction: Third-party price target
Discover the ripple (XRP) price predictions for 2025 and beyond, with analyst price targets and CFDs trading strategies on Capital.com
15:29, 6 February 2025
Apple (AAPL) stock price forecast: third-party price target
We looked at the forecasts for Apple stock in 10 years to see where the price would likely be at that point and the challenges the company could face. Read more.
11:22, 6 February 2025
FARTCOIN price prediction: Third-party price target
Read our FARTCOIN price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:18, 29 January 2025
MELANIA coin ($MELANIA) price prediction: Third party price target
Read our MELANIA crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts.
11:33, 22 January 2025
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:52, 22 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025People also watch
Still looking for a broker you can trust?
Join the 690,000+ traders worldwide that chose to trade with Capital.com